Fluoroquinolines: Past, present and future of a novel group of antibacterial agents

American Journal of Pharmaceutical Education

Volumn 66, Issue 2, 2002, Pages 164-172

  Scholar, Eric M ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Department of Pharmacology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745294571     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Owens, R.C. and Ambrose, P.G., "Clinical use of the fluoroquinolones," Medical Clin. N.A., 84, 1447-1469(2000).
2. Andriole, V., The Quinolones, Academic Press, New York NY(1998).
3. Kuhlmann, J., Dalhoff, A. and Zeiler, H.-J., Quinolone Antibacterials, Springer-Verlag, New York NY(1998).
4. Gootz, T.D. and Brighty, K.E., "Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects," Med. Res. Revs., 16, 433-486(1996).
5. Eliopoulos, G.M., "In vitro activity of new quinolone antimicrobial agents," in Microbiology, (edit., Leive, L.), Amer. Soc. Microbiol., Washington DC (1986) pp. 219-221.
6. Wiedemann, B. and Grimm, H., "Susceptibility to antibiotics: Species incidence and trends," in Antibiotics in Laboratory Medicine, (edit., Lorian, V.), Williams & Wilkins, Baltimore MD (1996) pp. 900-1168.
7. Gleckman, R., "What do the new antimicrobials offer?," Post Grad. Med., 109, 87-91(2001).
8. Appelbaum, P.C. and Hunter, P.A., "The fluoroquinolone antimicrobials: Past, present and future prospectives," Inter. J Antimicrob. Agents, 16, 5-15(2000).
9. Talan, D.A., "Clinical perspectives on new antimicrobials: Focus on fluoroquinolones," Clin. Infect. Dis., 32(Suppl.1), 564-571(2001).
10. Eliopoulos, G.M., Wennersten, C.B. and Moellering, Jr R.C., "Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria," Diagn. Microbiol. Infect. Dis., 25, 35-41(1996).
11. Von Eiif, C. and Peters, G., "In vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci," J. Antimicrob. Chemother., 38, 259-263(1996).
12. Wolfson, J.S. and Hooper, D.C., "Fluoroquinolone antimicrobial agents," Clin. Microbiol. Rev., 2, 378-424(1989).
13. Suh, B. and Lorber, B., "Quinolones," Med. Clin. North America, 79, 869-894(1995).
14. Phillips, I., King, A. and Shannon, K., "In vitro properties of the quinolones," in The Quinolones, (edit., Andriole, V.T.), Academic Press, New York NY (1998) pp. 81-116.
15. Gay, J.D., DeYoung, D.R. and Roberts, G.D., "In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. cheloni, M. fortuitum and M. kansasii," Antimicrob. Agents Chemother., 26, 94-96(1984).
16. Fenlon, C.H. and Cynamon, M.H., "Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellular," Antimicrob. Agents Chemother., 29, 386-388(1986).
17. Von Rosenstiel, N. and Adam, D. "Quinolone antibacterials. An update of their pharmacology and therapeutic use," Drugs, 47, 872-901(1994).
18. Neu, H.C., "Major advances in antibacterial quinolone therapy," Adv. Pharmacol., 29A, 227-262(1994).
19. Spangler, S.K., Jacobs, M.R. and Appelbaum, P.C., "Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes," Antimicrob. Agents Chemother., 38, 2471-2476(1994).
20. Hooper, D.C., "New uses for new and old quinolones and the challenge of resistance," Clin. Infect. Dis., 30, 243-254(2000).
21. Hooper, D.C., "Mechanisms of fluoroquinolone action," Clin. Infect. Dis., 32(Suppl. 1), 59-15(2001).
22. Scholar, E.M. and Pratt, W., The Antimicrobial Drugs, 2nd ed., Oxford University Press, New York NY (2000).
23. Drlica, K. and Zhao, X.L., "DNA gyrase, topoisomerase IV, and the 4-quinolones," Mol. Biol. Rev., 61, 377-392(1997).
24. Shea, M.E., and Hiasa, H., "Interactions between DNA helicases and frozen topisomerase IV -quinolone-DNA ternary complexes," J. Biol. Chem., 274, 22747-22754(1999).
25. Willmott, C.J., Critchlow, S.E., Eperon, I.C. and Maxwell, A., "The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase," J. Mol. Biol., 242, 351-366 (1994).
26. Martinez, J.L., Alono, A., Gomez-Gomez, J.M. and Baquero, F., "Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?," J. Antimicrobial Chemotherapy, 42, 683-688(1998).
27. Weidemann, B. and Heisig, P., "Mechanisms of quinolone resistance," Infection, 22(Suppl. 2), S73-S79(1994).
28. Everett, M.J. and Piddock, L.J.V., "Mechanisms of resistance to fluoroquinolones," in Quinolone Antibacterials, (edit., Kuhlmann, J., Dalhoff, A. and Zeiler, H.-J.), Springer-Verlag, New York NY (1998) pp. 260-296.
29. Hooper, D.C., "Emerging mechanisms of fluoroquinolone resistance," Emer. Infect. Dis., 7, 337-341(2001).
30. Poole, K., "Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria," Antimicrob. Agents Chemo., 44, 223-2241(2000).
31. Drlica, K., "The future of fluoroquinolones," Ann. Med., 32, 585-587(2000).
32. Thomson, K.S., "Minimizing quinolone resistance: are the new agents more or less likely to cause resistance?," J. Antimicrob. Chemo., 45, 719-723(2000).
33. Brown, E.M. and Reeves, D.S., "Quinolones," in Antibiotic and Chemotherapy, (edit., O'Grady, F., Lambert, H.P., Finch, R.G. and Greenwood, D.), Churchill Livingstone, New York NY(1997) pp. 419-452.
34. Schentag, J.J., Nix, D.E. and Wise, R., "Pharmacokinetics and tissue penetration of quinolones," in The New Generation of Quinolones, (edit., Siporin C., Heifetz C. and Domagala, J.), Marcel Dekker, New York NY(1990) pp. 189-222.
35. Robson, R.A., "Quinolone pharmacokinetics," Intern. J. Antimicrob. Agents, 2, 3-7(1992).
36. Gerding, D.N. and Hitt, J.A., "Tissue penetration of the new quinolones in humans," Rev. Infect. Dis., 11(Suppl. 5), S1046-S1057(1989).
37. Malmborg, A.S. and Rannikko, S., "Enoxacin distribution in human tissues after multiple oral administration," J. Antimicrob. Chemother., 21(Suppl. B), 57-60(1988).
38. Duben, W., Student, A., Jablonski, M. and Malottke, R., "Tissue concentration and effectiveness of ofloxacin in surgical patients," Infection, 14(Suppl. 1), S70-S72(1986).
39. Waldron, R., Arkell, D.G., Wise, R. and Andrews, J.M., "The intraprostatic penetration of ciprofloxacin," J. Antimicrob. Chemother., 17(4), S44-S45(1986).
40. Naber, K.G., Adam, D., Wittenberger, R. and Bartosik-Wich, B., "In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections," Infection, 14(Suppl. 1), S60-S64(1986).
41. Wolff, M., Boutron, L., Singlas, E., Clair, B., Decazed, J.M. and Regnier, B., "Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis," Antimicrob. Agents Chemother., 31, 899-902(1987).
42. Bergan, T., "Pharmacokinetics of fluorinated quinolones," in The Quinolones, (edit., Andriole, V.T.,), Academic Press, New York NY(1988) pp. 143-182.
43. Craig, W.A. and Suh, B., "Protein binding and the antibacterial effects. Methods for the determination of protein binding," in Antibiotics in Laboratory Medicine, (edit., Lorian, V.), Williams and Wilkins, Baltimore MD (1991) pp. 367-402.
44. Fillastre, J.P., Leroy, A. and Humbert, G., "Ofloxacin pharmacokinetics in renal failure," Antimicrob. Agents Chemother., 31, 156-160(1987).
45. Ball, P., "The quinolones. History and overview," in The Quinolones, (edit., Andriole, V.), Academic Press, New York NY (1998) pp. 1-28
46. Childs, S.J., "Quinolones for the Urinary Tract," in The New Generation of Quinolones, (edit., Siporin, C.), Marcel Dekker, New York NY (1990) pp. 223-242.
47. Nicolle, L.E., "Use of quinolones in urinary tract infection and prostatitis," in The Quinolones, (edit., Andriole V.T.), Academic Press, New York NY (1998) pp. 183-202.
48. Hamer, D.H. and Gorbach, S.L., "Use of the quinolones for the treatment and prophylaxis of bacterial gastrointestinal infections," in The Quinolones, (edit., Andriole, V.T.), Academic Press, New York NY, (1998) pp. 267-285.
49. Gotuzzo, E. and Carrillo, C., "Mini review: Quinolones in typhoid fever," Infect. Dis. Clin. Pract., 3, 345-349(1994).
50. Green, S. and Tillotson, G., "Use of ciprofloxacin in developing countries," Pediatr. Infect. Dis. J., 16, 150-159(1997).
51. Caeiro, J.P. and DuPont, H., "Management of travelers' diarrhea," Drugs, 56, 73-81(1998).
52. Wistrom, J. and Norrby, R., "Antibiotic prophylaxis of travelers' diarrhoea," Scand. J. Infect. Dis., 22(Suppl. 70), 111-129(1990).
53. DuPont, H.L. and Ericsson, C.D., "Prevention and treatment of traveler's diarrhea," New Engl. J. Med., 328, 1821-1827(1993).
54. Salam, I., Katelaris, P., Leigh-Smith, S. and Farthing, M.J.G., "Randomized trial of single-dose ciprofloxacin for travelers' diarrhea," Lancet, 344, 1537-1539(1994).
55. DiCarlo, R.P. and Martin, D.H., "Use of the quinolones in sexually transmitted diseases," in The Quinolones, (edit., Andriole, V.T.), Academic Press, New York NY (1998) pp. 203-227.
56. Saavedra, S., Rivera-Vazquez, C.R. and Ramirez-Ronda, C.H., "Quinolones and sexually transmitted diseases," in The New Generation of Quinolones, (edit., Sipporin, C., Heifetz, C. and Domagala, J.), Marcel Dekker, New York NY (1990) pp. 277-287.
57. Hook, E.W., Pinson, G.B., Blalock, C.J. and Johnson, R.B., "Dose-ranging study of CP99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea," Antimicrob. Agents Chemother., 40, 1720-1721(1996).
58. Haria, M. and Lamb, H.M., "Trovafloxacin," Drugs, 54, 435-445(1997).
59. Yu, V.L. and Vergis, E., "New macrolides or new quinolones as monotherapy for patients with community acquired pneumonia," Chest, 113, 1158-1159(1998).
60. Stein, G. and Havlichek, D., "Newer oral antimicrobials for resistant respiratory tract pathogens. Which show the most promise?," Postgrad. Med., 103, 67-70(1998).
61. Grossman, R.F., "The role of fluoroquinolones in respiratory tract infections," J. Antimicrob. Chemother., 40(Suppl. A), 59-62(1997).
62. Chenoweth, C.E., Saint, S., Martinez, F., Lynch, J.P. and Fendrick, A.M., "Antimicrobial resistance in streptococcus pneumoniae: Implications for patients with community-acquired pneumonia," Mayo Clin. Procs., 75, 1161-1168(2000).
63. LeBel, M., "Fluoroquinolones in the treatment of cystic fibrosis: A critical appraisal," Eur. J. Clin. Microb. Infect. Dis., 10, 316-324(1991).
64. Lew, D.P. and Waldvogel, F.A., "Quinolones and osteomyelitis, state-of-the-art," Drugs, 49(Suppl. 2), 100-111(1995).
65. Gentry, L.O. and Rodriguez-Gomez, G., "Ofloxacin versus parenteral therapy for chronic osteomyelitis," Antimicrob. Agents Chemother., 35, 538-541(1991).
66. Jauregui, L. and McInnes, S., "Therapy of gastrointestinal, central nervous system, and bone infections with new quinolones," in The New Generation of Quinolones, (edit., Siporin, C., Heifetz, C. and Domagala, J.), Marcel Dekker, New York NY (1990) pp. 289-316.
67. Gentry, L.O., "Oral antimicrobial therapy for osteomyelitis," Ann. Intern Med., 114, 986-987(1991).
68. Waldvogel, F.A., "Use of quinolones for the treatment of osteomyelitis and septic arthritis," Rev. Infect. Dis., 11(Suppl. 5), S1259-1263(1989).
69. Leysen, D.C., Haemers, A. and Pattyn, S.R., "Mycobacteria and the new quinolones," Antimicrob. Agents Chemother., 33, 1-5(1989).
70. Garcia-Rodriguez, J.A. and Garcia, A.C.G., "In-vitro activities of quinolones against mycobacteria," J. Antimicrob. Chemother., 32, 797-808(1993).
71. Gelber, R.H., Iranmanesh, A., Murray, L., Siu, P. and Tsang, M., "Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice," Antimicrob. Agents Chemother., 36, 2544-2547(1992).
72. Alangaden, G.J. and Lerner, S.A., "The clinical use of fluoroquinolones for the treatment of mycobacterial diseases," Clin. Infect. Dis., 25, 1213-1221(1997).
73. Jacobs, M.R., "Activity of quinolones against mycobacteria," Drugs, 49(Suppl. 2), 67-75(1995).
74. Meunier, F., Zinner, S.H., Gaya, H., Calandra, T., Viscoli, C., Klastersky, J. and Glauser, M., "Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors," Antimicrob. Agents Chemother., 35, 873-878(1991).
75. Davis, R., Markham, A. and Balfour, J.A., "Ciprofloxacin: An updated review of its pharmacology, therapeutic efficacy and tolerability," Drugs, 51, 1019-1074(1996).
76. Dembry, L.M., Farrington, J.M. and Andriole, T., "Fluoroquinolone antibiotics: Adverse effects and safety profiles," Infect. Dis. Clin. Prac., 8, 421-428(1999).
77. Nakamura, M., Abe, S., Goto, Y., Chishaki, A., Akazawa, K. and Kato, M., "In vivo assessment of prevention of white-noise-induced seizure in magnesium-deficient rats by N-methyl-D-aspartate receptor blockers," Epilepsy Res., 17, 249-256(1994).
78. Williams, P.D. and Helton, D.R., "The proconvulsive activity of quinolone antibiotics in an animal model," Toxicol. Lett., 58, 23-28(1991).
79. Christ, W. and Esch, B., "Adverse reactions to fluoroquinolones in adults and children," Infect. Dis. Clin. Pract., 3(Suppl. 3), S168-S176(1994).
80. Stahlmann, R. and Lode, H., "Safety overview. Toxicity, adverse effects, and drug interactions," in The Quinolones, (edit., Andriole, V.T.), Academic Press, New York NY(1998) pp. 369-415.
81. Takayama, S., Hirohashi, M., Kato, M. and Shimada, H., "Toxicity of quinolone antibacterial agents," J. Toxicol. Environ. Health, 45, 1-45(1995).
82. Vassileva, S.G., Mateev, G. and Parish, L.C., "Antimicrobial photosensitive reactions," Arch. Int. Med., 158, 1993-2000(1998).
83. Domagala, J.M., "Structure-activity and structure-side-effect relationships for the quinolone antibacterials," J. Antimicrob. Chemother., 33, 685-706(1994).
84. Gough, A.W., Kasal, O.B., Sigler, R.E. and Baragi, V., "Quinolone arthropathy-acute toxicity to immature cartilage," Toxicol. Pathol., 20, 436-449(1992)
85. Forster, C., Kociok, K., Shakibaei, M., Merker, H.J., Vormann, J., Günther, T. and Stahlmann, R., "Integrins on joint cartilage chondrocytes and alterations by magnesium deficiency in immature rats," Arch. Toxicol., 70, 261-270(1996).
86. Forster, C., Schwabe, L., Loze, E., Zippel, U., Vormann, J., Gunther, T., Merker, H.J. and Stahlmann, R., "Quinolone induced arthropathy: Exposure of magnesium-deficient aged rats or immature rats, nimeral concentrations in target tissues and pharmacokinetics," Arch. Toxicol., 72, 26-32(1997).
87. Christ, W. and Lehnert, T., "Toxicity of the quinolones," in The New Generation of Quinolones, (edit., Siporin, C., Heifetz, C.L. and Domagala, J.M.), Marcel Dekker, New York NY (1990) pp. 165-187.
88. Jaillon, P., Morganroth, J., Brump, I., Talbot, G. and the Sparfloxacin Safety Group, "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin," J. Antimicrob. Chemother., 37(Suppl. A), 161-167(1996).
89. Ball, P., "Quinolone-induced QT interval prolongation: A not-so-unexpected class effect," J. Antimicrob. Chemo., 45, 557-559(2000).
90. Wolfson, J.S., "Quinolone antimicrobial agents: adverse effects and bacterial resistance," Eur. J. Clin. Microbiol. Infect. Dis. 8, 1080-1092(1989).
91. Paton, J.H. and Reeves, D.S., "Clinical features and management of adverse effects of quinolone antibacterials," Drug Safety, 6, 8-27(1991).
92. Blum, M.D., Graham, D.J. and McCloskey, C.A., "Temafloxacin syndrome. Review of 95 cases," Clin. Infect. Dis., 18, 946-950(1994).
93. Ball, P. and Tillotson, G., "Tolerability of fluoroquinolone antibiotics," Drug Safety, 13, 343-358(1995).
94. Flor, S., Guay, D.R.P., Opsah, J.A., Tack, L.K. and Matzke, G.R., "Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin," Antimicrob. Agents Chemother., 34, 2436-2438(1990).
95. Wijnands, W.J.A., Vree, T.B. and van Heerwarden, C.L.A., "The influence of quinolone derivatives on theophylline clearance," Br. J. Clin. Pharmacol., 22, 677-683(1986).
96. Maesen, P.P., Teengs, P., Baur, C., and Davies, B.I., "Quinolones and raised plasma concentrations of theophylline," Lancet, 2, 530(1984).
97. Janknegt, R., "Drug interactions with quinolones," J. Antimicrob. Chemother., 26(Suppl. D), 7-29(1990).
98. Toon, S., Hopkins, K.J., Garstang, F.M., Aarons, L., Sedman, A. and Rowland, M., "Enoxacin-warfarin interaction: Pharmacokinetic and stereochemical aspects," Clin. Pharmacol. Ther., 42, 33-41(1987).
99. Akahane, K., Sekiguchi, M., Une, T. and Osada, Y., "Structure- epileptogenic relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites," Antimicrob. Agents Chemother., 331, 1704-1708(1989).